|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF800 |
Gene summary for ZNF800 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF800 | Gene ID | 168850 |
| Gene name | zinc finger protein 800 | |
| Gene Alias | ZNF800 | |
| Cytomap | 7q31.33 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q2TB10 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 168850 | ZNF800 | LZE4T | Human | Esophagus | ESCC | 6.69e-10 | 3.57e-01 | 0.0811 |
| 168850 | ZNF800 | LZE5T | Human | Esophagus | ESCC | 1.17e-06 | 1.66e-01 | 0.0514 |
| 168850 | ZNF800 | LZE7T | Human | Esophagus | ESCC | 4.98e-04 | 7.16e-02 | 0.0667 |
| 168850 | ZNF800 | LZE8T | Human | Esophagus | ESCC | 2.66e-02 | -4.40e-02 | 0.067 |
| 168850 | ZNF800 | LZE20T | Human | Esophagus | ESCC | 2.79e-14 | 3.22e-01 | 0.0662 |
| 168850 | ZNF800 | LZE24T | Human | Esophagus | ESCC | 8.31e-21 | 4.87e-01 | 0.0596 |
| 168850 | ZNF800 | P1T-E | Human | Esophagus | ESCC | 3.96e-22 | 8.80e-01 | 0.0875 |
| 168850 | ZNF800 | P2T-E | Human | Esophagus | ESCC | 8.64e-25 | 2.59e-01 | 0.1177 |
| 168850 | ZNF800 | P4T-E | Human | Esophagus | ESCC | 1.21e-23 | 5.68e-01 | 0.1323 |
| 168850 | ZNF800 | P5T-E | Human | Esophagus | ESCC | 4.41e-26 | 5.05e-01 | 0.1327 |
| 168850 | ZNF800 | P8T-E | Human | Esophagus | ESCC | 4.90e-26 | 4.59e-01 | 0.0889 |
| 168850 | ZNF800 | P9T-E | Human | Esophagus | ESCC | 1.51e-28 | 5.65e-01 | 0.1131 |
| 168850 | ZNF800 | P10T-E | Human | Esophagus | ESCC | 7.08e-23 | 5.12e-01 | 0.116 |
| 168850 | ZNF800 | P11T-E | Human | Esophagus | ESCC | 2.05e-15 | 4.08e-01 | 0.1426 |
| 168850 | ZNF800 | P12T-E | Human | Esophagus | ESCC | 1.34e-31 | 6.99e-01 | 0.1122 |
| 168850 | ZNF800 | P15T-E | Human | Esophagus | ESCC | 5.90e-24 | 5.12e-01 | 0.1149 |
| 168850 | ZNF800 | P16T-E | Human | Esophagus | ESCC | 4.51e-15 | 3.85e-01 | 0.1153 |
| 168850 | ZNF800 | P17T-E | Human | Esophagus | ESCC | 5.73e-08 | 2.45e-01 | 0.1278 |
| 168850 | ZNF800 | P19T-E | Human | Esophagus | ESCC | 8.65e-05 | 3.49e-01 | 0.1662 |
| 168850 | ZNF800 | P20T-E | Human | Esophagus | ESCC | 7.22e-15 | 2.27e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF800 | SNV | Missense_Mutation | c.942G>C | p.Arg314Ser | p.R314S | Q2TB10 | protein_coding | deleterious(0) | benign(0.354) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |
| ZNF800 | SNV | Missense_Mutation | novel | c.800G>A | p.Arg267Gln | p.R267Q | Q2TB10 | protein_coding | tolerated(0.17) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF800 | SNV | Missense_Mutation | rs774806951 | c.821N>T | p.Ser274Phe | p.S274F | Q2TB10 | protein_coding | tolerated(0.08) | benign(0.276) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ZNF800 | deletion | Frame_Shift_Del | c.1688delN | p.Lys563SerfsTer7 | p.K563Sfs*7 | Q2TB10 | protein_coding | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| ZNF800 | SNV | Missense_Mutation | c.1135N>G | p.Gln379Glu | p.Q379E | Q2TB10 | protein_coding | tolerated(0.44) | benign(0.181) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ZNF800 | SNV | Missense_Mutation | c.510N>G | p.Ile170Met | p.I170M | Q2TB10 | protein_coding | tolerated(0.23) | benign(0) | TCGA-Q1-A73Q-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| ZNF800 | SNV | Missense_Mutation | novel | c.1730C>A | p.Pro577His | p.P577H | Q2TB10 | protein_coding | tolerated(0.08) | benign(0.423) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF800 | SNV | Missense_Mutation | c.1799A>G | p.Tyr600Cys | p.Y600C | Q2TB10 | protein_coding | tolerated(0.16) | possibly_damaging(0.737) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF800 | SNV | Missense_Mutation | rs754742474 | c.443C>T | p.Ser148Leu | p.S148L | Q2TB10 | protein_coding | deleterious(0.03) | benign(0.104) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ZNF800 | SNV | Missense_Mutation | rs757156460 | c.749N>A | p.Arg250Gln | p.R250Q | Q2TB10 | protein_coding | tolerated(0.07) | benign(0.416) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |